BBI News and Press, Brickell Biotech Inc. From 06/18/20

Gainers:  Alpine Immune Sciences (NASDAQ: ALPN )  +174% . More news on: Alpine Immune Sciences, Inc., Aethlon Medical, Inc., Urban One, Inc., Stocks on the move, , Read more ...

Francesca's Holdings (NASDAQ: FRAN )  -24%  on Q1 results . More news on: Francesca's Holdings Corporation, Medley Management Inc., Brickell Biotech, Inc., Stocks on the move, , Read more ...

Brickell Biotech (NASDAQ: BBI ) has priced its public offering of 17.5M common shares, or pre-funded warrants to purchase common shares in-lieu of common stock and investor warrants to purchase up to same number common shares of common stock. More news on: Brickell Biotech, Inc...

BOULDER, Colo., June 17, 2020 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today ann...

Gainers:  Cohen & Company (NYSEMKT: COHN ) +128% . More news on: Cohen & Company Inc., LM Funding America, Inc., Integrated Media Technology Limited, Stocks on the move, , Read more ...

Urban One (NASDAQ: UONE ) -24% . More news on: Urban One, Inc., The9 Limited, China HGS Real Estate Inc., Stocks on the move, , Read more ...

Gainers: Urban One (NASDAQ: UONE ) +167% . More news on: Urban One, Inc., Edesa Biotech, Inc., Net Element, Inc., Stocks on the move, , Read more ...

Edesa Biotech (NASDAQ: EDSA ) +218%  on launch of COVID-19 study in Canada. More news on: Edesa Biotech, Inc., Brickell Biotech, Inc., BioHiTech Global, Inc., Stocks on the move, , Read more ...

Are These Penny Stocks To Buy Or Avoid This Week? When it comes to penny stocks , things can change at a moment’s notice. We saw this first-hand over the last few days. On Friday, there were several stocks under $5 that finished the week strong. But if you were to look at them on Monda...

Thinly traded nano cap Brickell Biotech (NASDAQ: BBI ) is up  118%  premarket on increased volume in reaction to positive data from a Japan-based Phase 3 clinical trial evaluating lead candidate topical sofpironium bromide gel, 5% in patients with primary axillary hyperhidrosis ...